Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756096 | 0.81 | RIPK1 (0.51) | ALDH1A1HTTMAPTHSP90AA1MEN1 | |
| SCHEMBL4756680 | 0.75 | HRH3 (0.43) | ALDH1A1HRH3MEN1KMT2AMAPK1 | |
| SCHEMBL4757016 | 0.74 | HSD11B1 (0.51) | ALDH1A1HTTHRH3HSD11B1 | |
| SCHEMBL4755631 | 0.74 | HSD11B1 (0.51) | ALDH1A1HTTHRH3HSD11B1 | |
| SCHEMBL4705412 | 0.73 | HSP90AA1 (0.44) | ALDH1A1HTTMAPTHSP90AA1MAPK1 | |
| SCHEMBL4704570 | 0.72 | HSD11B1 (0.45) | ALDH1A1MAPTHPGDTSHRHSD11B1 | |
| SCHEMBL4759002 | 0.72 | HSD11B1 (0.53) | ALDH1A1HTTHRH3MAPK1TSHR | |
| SCHEMBL4705470 | 0.71 | RUVBL1 (0.43) | MAPTTP53MEN1KMT2AMAPK1 | |
| SCHEMBL4789018 | 0.71 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL4704893 | 0.70 | DRD1 (0.44) | ALDH1A1GHSRMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 311/4885HTT 3487/4885HRH3 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.